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In Vitro Activities Against Clinical Isolates of Staphylococ-
cus aureus
A. Koteli ∗, A. Kakoulidou, S. Tsingene, M. Andronoglou
‘G. Gennimatas’ Thessaloniki General Hospital, Thessa-
loniki, Greece
Objectives: The objective of this study was to evaluate
and compare the in vitro activity against clinical isolates
of Staphylococcus aureus from varius species in a general
Hospital over a period of four years. Staphylococcus aureus
ATCC 29213 was used as quality control strains.
Methods: A total 3139 positive cultures between
2004—2005 and 3311 between 2006—2007 were tested. 107
strains between 2004—2005 and 121 between 2006—2007
were identiﬁed as Staphylococcus aureus. All specimens
were routinely inoculated into culture media. The blood
cultures were incubated in Bactec 9120 system (Becton Dick-
inson) for 7 days and in aerobic plus, anaerobic plus and
mycosis vials. Identiﬁcation of microorganisms and suscep-
tibility test was performed out with the Vitek 1 (BioMerieux,
France) for 2004—2005 and the Vitek 2 for 2006—2007 and
the susceptibility disc diffusion method according to CLSI
directions. Control of resistance to oxacillin was accom-
plished with oxacillin disk 1mg on Muller Hinton agar with
the addition of NaCl 4% and was conﬁrmed with the detec-
tion of PBP2a of MRSA (Slidex MRSA - BioMerieux). In
order to conﬁrm this we used the nutritious material BBLTM
CHROMagarTM MRSA of Becton Dickinson for 2006—2007. In
order to examine the production of b-lactamase we used
ceﬁnase discs (ceﬁnaseTM CEF-F) BioMerieux, France.
Results: The resistance rates (%) for 2004—2005 and
2006—2007 were: oxacillin 48/52, erythromycin 55/36,
rifampicin 14/6, ciproﬂoxacin 17/19, gentamycin 41/84,
clindamycin 17/20, tetracycline 39/44, linezolid 0/0, lev-
oﬂoxacin 10/12, quinopristin/dulfopristin 0/1, teicoplanin
8/0, vancomycin 8/0.
Conclusion: The resistance rates of Staphylococcus
aureus are very high although there is a small reduction of
the number of isolates in the last two years. The resistance
of Staphylococcus aureus to the antibiotics used appears to
vary during the four years of this study.
doi:10.1016/j.ijid.2008.05.732
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Linezolid Resistance Among Enterococci Correlates to the
Number of 23S G2576t Mutations and Duration of Therapy
I. Spiliopoulou1, V. Chini 1, F. Kolonitsiou1, E.D.
Anastassiou1,∗, E. Petinaki 2
1 University of Patras, Patras, Greece
2 University of Thessalia, Larissa, Greece
Background: Resistance to linezolid among enterococci
is associated with mutation G2576T in the domain V of 23S
rDNA, generating a new NheI restriction site. Duration of
linezolid treatment affects the emergence and the num-
ber of mutated 23S rDNA genes in enterococci, enhancing
persistence and spread of such resistant strains.
Methods: Fourteen linezolid-resistant and ﬁve suscep-
tible clinical isolates recovered from patients hospitalized
in ICUs of different hospitals were studied. Strain clonality
was analyzed by PFGE of SmaI DNA digests. Chromosomal
DNA was isolated and PCR of a 420 bp part in the V domain
of the 23S rRNA gene was performed. PCR products were
sequenced. Combination of EcoRI/NheI DNA digests coupled
with hybridization of a speciﬁc-domain V rDNA probe was
used and results were interpreted with respect to MIC lev-
els to linezolid, duration of treatment, and PFGE patterns
of strains. The number of hybridization bands digested with
EcoRI/NheI representing the number of mutated genes, as
compared to EcoRI alone representing the total number of
23S rDNA genes, was evaluated.
Results: Linezolid-resistant strains carried G2576T muta-
tion(s). The ratio of mutated alleles versus total 23S
rDNA genes was correlated with linezolid resistance lev-
els and duration of therapy. All ﬁve linezolid-sensitive and
eight resistant strains were isolated from patients with-
out prior antibiotic therapy, while six resistant strains
were recovered from patients under linezolid treatment.
Spread of the same resistant clones among patients without
prior linezolid exposure as those recovered from patients
treated with the speciﬁc agent was detected. Strains
carrying different number of mutated genes belonged
to the same clone, suggesting that strains with higher
copies of mutated alleles have evolved in the hospital
setting.
Conclusion: Even though duration of linezolid therapy
appears to be critical to development and level of resis-
tance, nosocomial transmission is a fact, underscoring strict
implementation of infection control measures.
doi:10.1016/j.ijid.2008.05.733
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Methicillin-Resistant Staphylococcus aureus (MRSA) and
MLSB (Macrolide-Lincosamide-Stretogramin B) Isolated
from Community and Hospital - Associated Infections
(Ca/Ha-MRSA)
L.M. Junie1,∗, D. Homorodean2
1 University of Medicine and Pharmacy, Cluj Napoca, Roma-
nia
2 The Laboratory of ‘Leon Daniello’ Pneumoftiziological
Hospital, Cluj Napoca, Romania
Background: MRSA is associated with an increasing num-
ber of both community and hospital-associated infections
(CA/HA-MRSA). Resistance to the macrolides (MLSB resis-
tance) in staphylococci may be due to an active efﬂux
mechanism (encoded by the mrsA gene) or to the modiﬁ-
cation of the ribosomal target (encoded by ermA or ermC
genes). MLSB resistance is either constitutive or inducible
by certain macrolides. Objective: The aim of our study was
to test the resistance of S. aureus strains isolated in Cluj
Napoca.
Method: Identiﬁcation was performed by APY sys-
tem (BioMerieux). The resistance proﬁles were performed
according to NCCLS by disk diffusion and dilution method in
Mueller-Hinton agar supplemented with 2% NaCl (oxacillin)
to Gentamicin, Tobramycin, Lyncomycin, Erythromycin,
